Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

19. Referanser

Adams, S. C., DeLorey, D. S., Davenport, M. H., Fairey, A. S., North, S., & Courneya, K. S. (2018). Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer, 118(10), 1313-1321. https://doi.org/10.1038/s41416-018-0044-7

Adra, N., Abonour, R., Althouse, S. K., Albany, C., Hanna, N. H., & Einhorn, L. H. (2017). High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol, 35(10), 1096-1102. https://doi.org/10.1200/JCO.2016.69.5395

Adra, N., Albany, C., Sonneburg, D., Tong, Y., Hanna, N., & Einhorn, L. (2014). A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 2000 to 2010. J Clin Oncol, 31, (suppl; abstra 4557.

Adra, N., Althouse, S. K., Liu, H., Brames, M. J., Hanna, N. H., Einhorn, L. H., & Albany, C. (2016). Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol, 27(5), 875-879. https://doi.org/10.1093/annonc/mdw045

Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., . . . Hanna, N. H. (2018). Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol, 29(1), 209-214. https://doi.org/10.1093/annonc/mdx680

Al-Jebari, Y., Glimelius, I., Berglund Nord, C., Cohn-Cedermark, G., Stahl, O., Tandstad, T., . . . Giwercman, A. (2019). Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. PLoS Med, 16(6), e1002816. https://doi.org/10.1371/journal.pmed.1002816

Albany, C., & Einhorn, L. H. (2013). Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol, 25(3), 261-265. https://doi.org/10.1097/CCO.0b013e32835f085d

Albany, C., Kesler, K., & Cary, C. (2019). Management of Residual Mass in Germ Cell Tumors After Chemotherapy. Curr Oncol Rep, 21(1), 5. https://doi.org/10.1007/s11912-019-0758-6

Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., . . . Laguna, M. P. (2011). EAU Guidelines on Testicular Cancer: 2011 Update. European Urology, 60(2), 304-319.

Albers, P., Bender, H., Yilmaz, H., Schoeneich, G., Biersack, H. J., & Mueller, S. C. (1999). Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology, 53(4), 808-811.

Albers, P., Goll, A., Bierhoff, E., Schoeneich, G., & Muller, S. C. (1999). Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology, 54(4), 714-718.

Albers, P., Melchior, D., & Muller, S. C. (2003). Surgery in metastatic testicular cancer. Eur Urol, 44(2), 233-244. https://doi.org/10.1016/s0302-2838(03)00252-5

Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., . . . Hartmann, M. (2008). Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol, JCO.2007.2012.0899. https://doi.org/10.1200/jco.2007.12.0899

Alexander, E. J., White, I. M., & Horwich, A. (2010). Update on management of seminoma. Indian J Urol, 26(1), 82-91. https://doi.org/10.4103/0970-1591.60451

Almstrup, K., Lobo, J., Morup, N., Belge, G., Rajpert-De Meyts, E., Looijenga, L. H. J., & Dieckmann, K. P. (2020). Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol, 17(4), 201-213. https://doi.org/10.1038/s41585-020-0296-x

Andreassen, K. E., Grotmol, T., Cvancarova, M. S., Johannesen, T. B., & Fossa, S. D. (2011). Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer, 129(12), 2867-2874. https://doi.org/10.1002/ijc.25943

Aparicio, J., Germa, J. R., Garcia del Muro, X., Maroto, P., Arranz, J. A., Saenz, A., . . . Sanchez, A. (2005). Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol, 23(34), 8717-8723. 


Aparicio, J., Maroto, P., del Muro, X. G., Guma, J., Sanchez-Munoz, A., Margeli, M., . . . Germa, J. R. (2011). Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol, 29(35), 4677-4681. https://doi.org/10.1200/JCO.2011.36.0503

Bachner, M., Loriot, Y., Gross-Goupil, M., Zucali, P. A., Horwich, A., Germa-Lluch, J. R., . . . De Santis, M. (2011). 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol


Balawender, K., Orkisz, S., & Wisz, P. (2018). Testicular microlithiasis: what urologists should know. A review of the current literature. Cent European J Urol, 71(3), 310-314. https://doi.org/10.5173/ceju.2018.1728

Bamberg, M., Schmidberger, H., Meisner, C., Classen, J., Souchon, R., Weinknecht, S., . . . Flink, M. (1999). Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer, 83(6), 823-827.

Bang, A. K., Petersen, J. H., Petersen, P. M., Andersson, A. M., Daugaard, G., & Jorgensen, N. (2009). Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys, 75(3), 672-676. https://doi.org/10.1016/j.ijrobp.2008.11.057

Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995). Late relapse of testicular cancer. J Clin Oncol, 13(5), 1170-1176.

Baniel, J., Foster, R. S., Rowland, R. G., Bihrle, R., & Donohue, J. P. (1994). Complications of primary retroperitoneal lymph node dissection. J Urol, 152(2 Pt 1), 424-427.

Beck, S. D., Peterson, M. D., Bihrle, R., Donohue, J. P., & Foster, R. S. (2007). Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. J Urol, 178(2), 504-506; discussion 506. https://doi.org/10.1016/j.juro.2007.03.123

Besse, B., Grunenwald, D., Flechon, A., Caty, A., Chevreau, C., Culine, S., . . . Fizazi, K. (2009). Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg, 137(2), 448-452. https://doi.org/10.1016/j.jtcvs.2008.09.032

Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., . . . Wittekind, C. (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 24(4), 878-888. https://doi.org/10.1093/annonc/mds579

Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., . . . Wittekind, C. (2012). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncology.

Bezan, A., Posch, F., Ploner, F., Bauernhofer, T., Pichler, M., Szkandera, J., . . . Stotz, M. (2017). Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One, 12(4), e0176283. https://doi.org/10.1371/journal.pone.0176283

Bhala, N., Coleman, J. M., Radstone, C. R., Horsman, J. M., George, J., Hancock, B. W., . . . Coleman, R. E. (2004). The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol), 16(1), 40-47. https://doi.org/10.1016/s0936-6555(03)00166-3

Bjerner, J., Biernat, D., Fossa, S. D., & Bjoro, T. (2009). Reference intervals for serum testosterone, SHBG, LH and FSH in males from the NORIP project. Scand J Clin Lab Invest, 69(8), 873-879 e871-811. https://doi.org/10.3109/00365510903380886

Bokemeyer, C., Hartmann, J. T., Fossa, S. D., Droz, J. P., Schmol, H. J., Horwich, A., . . . Einhorn, L. (2003). Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS, 111(1), 49-59; discussion 59-63. https://doi.org/10.1034/j.1600-0463.2003.11101081.x

Bokemeyer, C., Kollmannsberger, C., Stenning, S., Hartmann, J. T., Horwich, A., Clemm, C., . . . Oliver, T. (2004). Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer, 91(4), 683-687. https://doi.org/10.1038/sj.bjc.6602020

6602020 [pii]

Bokemeyer, C., Nichols, C. R., Droz, J. P., Schmoll, H. J., Horwich, A., Gerl, A., . . . Hartmann, J. T. (2002). Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol, 20(7), 1864-1873.

Bokemeyer, C., Oechsle, K., Honecker, F., Mayer, F., Hartmann, J. T., Waller, C. F., . . . Kollmannsberger, C. (2008). Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol, 19(3), 448-453. 


Bower, J. E., Bak, K., Berger, A., Breitbart, W., Escalante, C. P., Ganz, P. A., . . . American Society of Clinical, O. (2014). Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol, 32(17), 1840-1850. https://doi.org/10.1200/JCO.2013.53.4495

Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., . . . Radiation Therapy Oncology, G. (2013). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol, 15(10), 1429-1437. https://doi.org/10.1093/neuonc/not114

Brydoy, M., Fossa, S. D., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., & Dahl, O. (2005). Paternity following treatment for testicular cancer. J Natl Cancer Inst, 97(21), 1580-1588. https://doi.org/10.1093/jnci/dji339

Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., . . . Fossa, S. D. (2009). Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst, 101(24), 1682-1695. https://doi.org/10.1093/jnci/djp413

Busch, J., Seidel, C., & Zengerling, F. (2016). Male Extragonadal Germ Cell Tumors of the Adult. Oncol Res Treat, 39(3), 140-144. https://doi.org/10.1159/000444271

Calaway, A. C., Tachibana, I., Masterson, T. A., Foster, R. S., Einhorn, L. H., & Cary, C. (2019). Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors. Urology, 127, 74-79. https://doi.org/10.1016/j.urology.2019.02.014

Capelouto, C. C., Clark, P. E., Ransil, B. J., & Loughlin, K. R. (1995). A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol, 153(3 Pt 2), 981-985.

Carver, B. S., Cronin, A. M., Eggener, S., Savage, C. J., Motzer, R. J., Bajorin, D., . . . Sheinfeld, J. (2010). The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology, 75(6), 1431-1435. https://doi.org/10.1016/j.urology.2009.11.076

Cathomas, R., Klingbiel, D., Bernard, B., Lorch, A., Garcia Del Muro, X., Morelli, F., . . . Beyer, J. (2018). Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol, JCO1800210. https://doi.org/10.1200/JCO.18.00210

Cheney, S. M., Andrews, P. E., Leibovich, B. C., & Castle, E. P. (2015). Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int, 115(1), 114-120. https://doi.org/10.1111/bju.12804

Cho, J. S., Kaimakliotis, H. Z., Cary, C., Masterson, T. A., Beck, S., & Foster, R. (2017). Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int, 120(1), 104-108. https://doi.org/10.1111/bju.13844

Christensen, T. B., Engbaek, F., Marqversen, J., Nielsen, S. I., Kamby, C., & von der Maase, H. (1999). 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer, 80(10), 1577-1581. https://doi.org/10.1038/sj.bjc.6690565

Christian, J. A., Huddart, R. A., Norman, A., Mason, M., Fossa, S., Aass, N., . . . Horwich, A. (2003). Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol, 21(5), 871-877. https://doi.org/10.1200/JCO.2003.05.155

Chung, P. W., Daugaard, G., Tyldesley, S., Panzarella, T., Kollmannsberger, C. K., Gospodarowicz, M., & Warde, P. (2010). Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol, 28(7s), suppl; abstr 4535.

Chung, P. W., Gospodarowicz, M. K., Panzarella, T., Jewett, M. A., Sturgeon, J. F., Tew-George, B., . . . Warde, P. R. (2004). Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol, 45(6), 754-759; discussion 759-760. https://doi.org/10.1016/j.eururo.2004.01.020

Classen, J., Schmidberger, H., Meisner, C., Souchon, R., Sautter-Bihl, M. L., Sauer, R., . . . Bamberg, M. (2003). Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol, 21(6), 1101-1106.

Coogan, C. L., Foster, R. S., Simmons, G. R., Tognoni, P. G., Roth, B. J., & Donohue, J. P. (1998). Bilateral testicular tumors: management and outcome in 21 patients. Cancer, 83(3), 547-552.

Crona, D. J., Faso, A., Nishijima, T. F., McGraw, K. A., Galsky, M. D., & Milowsky, M. I. (2017). A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist, 22(5), 609-619. https://doi.org/10.1634/theoncologist.2016-0319

Culine, S., Kramar, A., Theodore, C., Geoffrois, L., Chevreau, C., Biron, P., . . . Genito-Urinary Group of the French Federation of Cancer Centers Trial, T. M. (2008). Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol, 26(3), 421-427. https://doi.org/10.1200/JCO.2007.13.8461

Daneshmand, S., Albers, P., Fossa, S. D., Heidenreich, A., Kollmannsberger, C., Krege, S., . . . Wood, L. (2012). Contemporary management of postchemotherapy testis cancer. Eur Urol, 62(5), 867-876. https://doi.org/10.1016/j.eururo.2012.08.014

Daugaard, G., Petersen, P. M., & Rorth, M. (2003). Surveillance in stage I testicular cancer. APMIS, 111(1), 76-83; discussion 83-75. https://doi.org/10.1034/j.1600-0463.2003.11101111.x

Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., . . . Schmoll, H. J. (2010). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol


De Giorgi, U., Rosti, G., Aieta, M., Testore, F., Burattini, L., Fornarini, G., . . . Marangolo, M. (2006). Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol, 50(5), 1032-1038; discussion 1038-1039. 


De Giorgi, U., Rosti, G., Papiani, G., Aieta, M., Fochessati, F., Paoluzzi, L., . . . Marangolo, M. (2004). Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol, 27(5), 457-460. 

De Santis, M., Becherer, A., Bokemeyer, C., Stoiber, F., Oechsle, K., Sellner, F., . . . Pont, J. (2004). 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 22(6), 1034-1039. https://doi.org/10.1200/JCO.2004.07.188

JCO.2004.07.188 [pii]

de Wit, M., Brenner, W., Hartmann, M., Kotzerke, J., Hellwig, D., Lehmann, J., . . . Bares, R. (2008). [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol, 19(9), 1619-1623. https://doi.org/10.1093/annonc/mdn170

de Wit, R., Roberts, J. T., Wilkinson, P. M., de Mulder, P. H., Mead, G. M., Fossa, S. D., . . . Collette, L. (2001). Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 19(6), 1629-1640.

de Wit, R., Skoneczna, I., Daugaard, G., De Santis, M., Garin, A., Aass, N., . . . Collette, L. (2012). Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol, 30(8), 792-799. https://doi.org/10.1200/JCO.2011.37.0171

de Wit, R., Sleijfer, S., Kaye, S. B., Horwich, A., Mead, B., Sleijfer, D. T., & Stoter, G. (2007). Bleomycin and scuba diving: where is the harm? Lancet Oncol, 8(11), 954-955. https://doi.org/10.1016/S1470-2045(07)70321-2

Del Risco Kollerud, R., Blaasaas, K. G., Claussen, B., Nafstad, P., Cannon-Albright, L. A., Ruud, E., . . . Naess, O. (2018). Family history of cancer and the risk of childhood solid tumours: a Norwegian nationwide register-based cohort study. Br J Cancer, 118(6), 905-912. https://doi.org/10.1038/bjc.2017.493

DeSantis, M., Albrecht, W., Holtl, W., & Pont, J. (1999). Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer, 83(6), 864-865.

Di Tonno, F., Tavolini, I. M., Belmonte, P., Bertoldin, R., Cossaro, E., Curti, P., . . . North-Eastern Uro-Oncological Group, I. (2009). Lessons from 52 patients with leydig cell tumor of the testis: the GUONE (North-Eastern Uro-Oncological Group, Italy) experience. Urologia Internationalis, 82(2), 152-157. https://doi.org/10.1159/000200790

Dieckmann, K. P., Albers, P., Classen, J., De Wit, M., Pichlmeier, U., Rick, O., . . . Kuczyk, M. (2005). Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol, 173(3), 824-829.https://pubmed.ncbi.nlm.nih.gov/15711278/


Dieckmann, K. P., Anheuser, P., Schmidt, S., Soyka-Hundt, B., Pichlmeier, U., Schriefer, P., . . . Ruf, C. G. (2015). Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction. BMC Urol, 15, 16. https://doi.org/10.1186/s12894-015-0010-0

Dieckmann, K. P., Bertolini, J., & Wulfing, C. (2019). Adult Granulosa Cell Tumor of the Testis: A Case Report with a Review of the Literature. Case Rep Urol, 2019, 7156154. https://doi.org/10.1155/2019/7156154

Dieckmann, K. P., Heinemann, V., Frey, U., Pichlmeier, U., & German Testicular Cancer Study, G. (2005). How harmful is contralateral testicular biopsy?--an analysis of serial imaging studies and a prospective evaluation of surgical complications. Eur Urol, 48(4), 662-672. https://doi.org/10.1016/j.eururo.2005.06.008

Dieckmann, K. P., Kulejewski, M., Pichlmeier, U., & Loy, V. (2007). Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol, 51(1), 175-183; discussion 183-175. 


Domont, J., Massard, C., Patrikidou, A., Bossi, A., de Crevoisier, R., Rose, M., . . . Fizazi, K. (2013). A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol, 31(5), 697-705. https://doi.org/10.1016/j.urolonc.2011.04.004

Donat, S. M., & Levy, D. A. (1998). Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol, 160(4), 1347-1352.

Donohue, J. P., & Foster, R. S. (1998). Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am, 25(3), 461-468. https://doi.org/10.1016/s0094-0143(05)70035-5

Doyle, D. M., & Einhorn, L. H. (2008). Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys, 70(5), 1361-1364. https://doi.org/10.1016/j.ijrobp.2007.11.005

Droz, J. P., Kramar, A., Biron, P., Pico, J. L., Kerbrat, P., Peny, J., . . . Culine, S. (2007). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol, 51(3), 739-746; discussion 747-738. 


Eastham, J. A., Wilson, T. G., Russell, C., Ahlering, T. E., & Skinner, D. G. (1994). Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology, 43(1), 74-80. https://doi.org/10.1016/s0090-4295(94)80269-6

Eberhard, J., Stahl, O., Giwercman, Y., Cwikiel, M., Cavallin-Stahl, E., Lundin, K. B., . . . Giwercman, A. (2004). Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. Hum. Reprod., 19(6), 1418-1425. https://doi.org/10.1093/humrep/deh231

Ehrlich, Y., Beck, S. D., Foster, R. S., Bihrle, R., & Einhorn, L. H. (2013). Serum tumor markers in testicular cancer. Urol Oncol, 31(1), 17-23. https://doi.org/10.1016/j.urolonc.2010.04.007

Ehrlich, Y., Brames, M. J., Beck, S. D., Foster, R. S., & Einhorn, L. H. (2010). Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol, 28(4), 531-536. https://doi.org/10.1200/JCO.2009.23.0714

Einhorn, L. H., Brames, M. J., Juliar, B., & Williams, S. D. (2007). Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol, 25(5), 513-516.


Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007). High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 357(4), 340-348.


Fankhauser, C. D., Grogg, J. B., Hayoz, S., Wettstein, M. S., Dieckmann, K. P., Sulser, T., . . . Hermanns, T. (2019). Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol, 101097JU0000000000000705. https://doi.org/10.1097/JU.0000000000000705

Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., . . . Cancer advisory, p. (2019). 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol, 20(10), e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5

Feldman, D. R., Lorch, A., Kramar, A., Albany, C., Einhorn, L. H., Giannatempo, P., . . . Powles, T. (2016). Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol, 34(4), 345-351. https://doi.org/10.1200/JCO.2015.62.7000

Feldman, D. R., Sheinfeld, J., Bajorin, D. F., Fischer, P., Turkula, S., Ishill, N., . . . Motzer, R. J. (2010). TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol, 28(10), 1706-1713. https://doi.org/10.1200/JCO.2009.25.1561

Fizazi, K., Delva, R., Caty, A., Chevreau, C., Kerbrat, P., Rolland, F., . . . Laplanche, A. (2014). A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol, 65(2), 381-386. https://doi.org/10.1016/j.eururo.2013.09.004

Fizazi, K., Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J. T., . . . Fromont, G. (2008). Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Annals of Oncology, 19(2), 259-264.

Fizazi, K., Pagliaro, L., Laplanche, A., Flechon, A., Mardiak, J., Geoffrois, L., . . . Culine, S. (2014). Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 15(13), 1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5

Fizazi, K., Prow, D. M., Do, K. A., Wang, X., Finn, L., Kim, J., . . . Amato, R. J. (2002). Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer, 86(10), 1555-1560. https://doi.org/10.1038/sj.bjc.6600272

Fizazi, K., Tjulandin, S., Salvioni, R., Germa-Lluch, J. R., Bouzy, J., Ragan, D., . . . Mahe, C. (2001). Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol, 19(10), 2647-2657. https://doi.org/10.1200/JCO.2001.19.10.2647

Flechon, A., Bompas, E., Biron, P., & Droz, J. P. (2002). Management of post-chemotherapy residual masses in advanced seminoma. J Urol, 168(5), 1975-1979. 

Forsberg, L., Dale, L., Hoiem, L., Magnusson, A., Mikulowski, P., Olsson, A. M., . . . Stenwig, A. E. (1986). Computed tomography in early stages of testicular carcinoma. Size of normal retroperitoneal lymph nodes and lymph nodes in patients with metastases in stage II A. A SWENOTECA study: Swedish-Norwegian Testicular Cancer Project. Acta Radiol Diagn (Stockh), 27(5), 569-574. https://doi.org/10.1177/028418518602700516

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. nr. 1208.

Fossa, S. D., Bokemeyer, C., Gerl, A., Culine, S., Jones, W. G., Mead, G. M., . . . Tjulandin, S. (1999). Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 85(4), 988-997.

Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., . . . Travis, L. B. (2007). Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst, 99(7), 533-544. 


Fossa, S. D., Kaye, S. B., Mead, G. M., Cullen, M., de Wit, R., Bodrogi, I., . . . Collette, L. (1998). Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol, 16(2), 716-724. https://doi.org/10.1200/JCO.1998.16.2.716

Fossa, S. D., Ous, S., Lien, H. H., & Stenwig, A. E. (1989). Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol, 141(3), 557-559. https://doi.org/10.1016/s0022-5347(17)40892-5

Fossa, S. D., Paluchowska, B., Horwich, A., Kaiser, G., de Mulder, P. H., Koriakine, O., . . . Group, E. G. (2005). Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer, 93(11), 1209-1214. https://doi.org/10.1038/sj.bjc.6602830

Fossa, S. D., Stenning, S. P., Gerl, A., Horwich, A., Clark, P. I., Wilkinson, P. M., . . . Cook, P. A. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer, 80(9), 1392-1399. https://doi.org/10.1038/sj.bjc.6690534

Fossa, S. D., Aass, N., Harvei, S., & Tretli, S. (2004). Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer, 90(3), 607-612. https://doi.org/10.1038/sj.bjc.6601558

Fossa, S. D., Aass, N., Winderen, M., Bormer, O. P., & Olsen, D. R. (2002). Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol, 13(2), 222-228.

Foster, R. S., Baniel, J., Leibovitch, I., Curran, M., Bihrle, R., Rowland, R., & Donohue, J. P. (1996). Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol, 155(6), 1943-1945.

Fox, E. P., Weathers, T. D., Williams, S. D., Loehrer, P. J., Ulbright, T. M., Donohue, J. P., & Einhorn, L. H. (1993). Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol, 11(7), 1294-1299. https://doi.org/10.1200/JCO.1993.11.7.1294

Frisina, R. D., Wheeler, H. E., Fossa, S. D., Kerns, S. L., Fung, C., Sesso, H. D., . . . Travis, L. B. (2016). Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol, 34(23), 2712-2720. https://doi.org/10.1200/JCO.2016.66.8822

Fung, C., Fossa, S. D., Milano, M. T., Oldenburg, J., & Travis, L. B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol, 31(30), 3807-3814. https://doi.org/10.1200/JCO.2013.50.3409

Gennaro, N., Sconfienza, L. M., Ambrogi, F., Boveri, S., & Lanza, E. (2019). Thermal ablation to relieve pain from metastatic bone disease: a systematic review. Skeletal Radiol, 48(8), 1161-1169. https://doi.org/10.1007/s00256-018-3140-0

George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., . . . Einhorn, L. H. (2003). Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol, 21(1), 113-122. https://doi.org/10.1200/JCO.2003.03.019

Gerdtsson, A., Hakansson, U., Tornblom, M., Jancke, G., Negaard, H. F. S., Glimelius, I., . . . Kjellman, A. (2019). Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.08.002

Gerl, A., Clemm, C., Schmeller, N., Hentrich, M., Lamerz, R., & Wilmanns, W. (1997). Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol, 8(1), 41-47. https://doi.org/10.1023/a:1008253323854

Germa-Lluch, J. R., Garcia del Muro, X., Tabernero, J. M., Sanchez, M., Aparicio, J., Alba, E., & Barnadas, A. (1999). BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol, 10(3), 289-293. https://doi.org/10.1023/a:1008351022211

Ghezzi, M., Berretta, M., Bottacin, A., Palego, P., Sartini, B., Cosci, I., . . . Garolla, A. (2016). Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor. Front Pharmacol, 7, 122. https://doi.org/10.3389/fphar.2016.00122

Ghodoussipour, S., & Daneshmand, S. (2020). Surgical strategies for postchemotherapy testis cancer. Transl Androl Urol, 9(Suppl 1), S74-S82. https://doi.org/10.21037/tau.2019.09.43

Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C. J., . . . Cary, C. (2016). Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol, 196(1), 95-100. https://doi.org/10.1016/j.juro.2015.12.082

Gizzi, M., Oberic, L., Massard, C., Poterie, A., Le Teuff, G., Loriot, Y., . . . Fizazi, K. (2016). Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 69, 151-157. https://doi.org/10.1016/j.ejca.2016.10.003

Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., . . . American Society of Clinical, O. (2012). Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 30(13), 1553-1561. https://doi.org/10.1200/JCO.2011.39.9436

Grogg, J., Schneider, K., Bode, P. K., Kranzbuhler, B., Eberli, D., Sulser, T., . . . Fankhauser, C. D. (2020). Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist. https://doi.org/10.1634/theoncologist.2019-0692

Groot, H. J., Lubberts, S., de Wit, R., Witjes, J. A., Kerst, J. M., de Jong, I. J., . . . Schaapveld, M. (2018). Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol, 36(24), 2504-2513. https://doi.org/10.1200/JCO.2017.77.4174

Gupta, S. K., Lindemulder, E. A., & Sathyan, G. (2000). Modeling of circadian testosterone in healthy men and hypogonadal men. J Clin Pharmacol, 40(7), 731-738. https://doi.org/10.1177/00912700022009486

Hale, G. R., Teplitsky, S., Truong, H., Gold, S. A., Bloom, J. B., & Agarwal, P. K. (2018). Lymph node imaging in testicular cancer. Transl Androl Urol, 7(5), 864-874. https://doi.org/10.21037/tau.2018.07.18

Hall, E. J., & Wuu, C. S. (2003). Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys, 56(1), 83-88.

Hamid, A. A., Markt, S. C., Vicier, C., McDermott, K., Richardson, P., Ho, V. T., & Sweeney, C. J. (2019). Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer, 17(1), 58-64 e51. https://doi.org/10.1016/j.clgc.2018.09.009

Handbook for reporting results of cancer treatment. (1979). Geneva, Switzerland

Harland, S. J., Cook, P. A., Fossa, S. D., Horwich, A., Mead, G. M., Parkinson, M. C., . . . Stenning, S. P. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol, 160(4), 1353-1357.

Hartmann, J. T., Candelaria, M., Kuczyk, M. A., Schmoll, H. J., & Bokemeyer, C. (1997). Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer, 33(6), 843-847.

Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J. P., Horwich, A., Gerl, A., . . . Bokemeyer, C. (2001). Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst, 93(22), 1733-1738. https://doi.org/10.1093/jnci/93.22.1733

Hartmann, J. T., Gauler, T., Metzner, B., Gerl, A., Casper, J., Rick, O., . . . German Testicular Cancer Study, G. (2007). Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol, 25(36), 5742-5747. https://doi.org/10.1200/JCO.2007.11.9099

Hartmann, J. T., & Lipp, H. P. (2006). Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf, 29(3), 209-230. https://doi.org/10.2165/00002018-200629030-00005

Hartmann, J. T., Nichols, C. R., Droz, J. P., Horwich, A., Gerl, A., Fossa, S. D., . . . Bokemeyer, C. (2000). Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst, 92(1), 54-61.

Hashimoto, K., Fujimoto, H., Kouno, T., Koseki, M., Yonemori, K., Hirata, T., . . . Fujiwara, Y. (2012). The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. Urol Oncol, 30(3), 319-324. https://doi.org/10.1016/j.urolonc.2010.02.008

Haugnes, H. S., Laurell, A., Stierner, U., Bremnes, R. M., Dahl, O., Cavallin-Stahl, E., & Cohn-Cedermark, G. (2012). High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol, 51(2), 168-176. https://doi.org/10.3109/0284186X.2011.641507

Haugnes, H. S., Oldenburg, J., & Bremnes, R. M. (2015). Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol, 33(9), 399-406. https://doi.org/10.1016/j.urolonc.2014.11.012

Haugnes, H. S., Stenklev, N. C., Brydoy, M., Dahl, O., Wilsgaard, T., Laukli, E., & Fossa, S. D. (2018). Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol, 57(8), 1075-1083. https://doi.org/10.1080/0284186X.2018.1433323

Haugnes, H. S., Wethal, T., Aass, N., Dahl, O., Klepp, O., Langberg, C. W., . . . Fossa, S. D. (2010). Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol, 28(30), 4649-4657.


Haugnes, H. S., Aass, N., Fossa, S. D., Dahl, O., Brydoy, M., Aasebo, U., . . . Bremnes, R. M. (2009). Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol, 27(17), 2779-2786. https://doi.org/10.1200/JCO.2008.18.5181

Haugnes, H. S., Aass, N., Fossa, S. D., Dahl, O., Klepp, O., Wist, E. A., . . . Bremnes, R. M. (2007). Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol, 18(2), 241-248.


Heidenreich, A., Albers, P., Hartmann, M., Kliesch, S., Kohrmann, K. U., Krege, S., . . . German Testicular Cancer Study, G. (2003). Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol, 169(5), 1710-1714. https://doi.org/10.1097/01.ju.0000060960.18092.54

Heidenreich, A., Paffenholz, P., Nestler, T., & Pfister, D. (2018). Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer. Oncol Res Treat, 41(6), 370-378. https://doi.org/10.1159/000489508

Heidenreich, A., Paffenholz, P., Nestler, T., Pfister, D., & Daneshmand, S. (2020). Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors. Curr Opin Urol, 30(2), 251-257. https://doi.org/10.1097/MOU.0000000000000736

Heidenreich, A., Pfister, D., Witthuhn, R., Thuer, D., & Albers, P. (2009). Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol, 55(1), 217-224. https://doi.org/10.1016/j.eururo.2008.09.027

Hellesnes, R., Kvammen, O., Myklebust, T. A., Bremnes, R. M., Karlsdottir, A., Negaard, H. F. S., . . . Haugnes, H. S. (2019). Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer. https://doi.org/10.1002/ijc.32704

Herr, H. W., Sheinfeld, J., Puc, H. S., Heelan, R., Bajorin, D. F., Mencel, P., . . . Motzer, R. J. (1997a). Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 157(3), 860-862.

Herr, H. W., Sheinfeld, J., Puc, H. S., Heelan, R., Bajorin, D. F., Mencel, P., . . . Motzer, R. J. (1997b). Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 157(3), 860-862. 

Hiester, A., Nini, A., Fingerhut, A., Grosse Siemer, R., Winter, C., Albers, P., & Lusch, A. (2018). Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. Front Surg, 5, 80. https://doi.org/10.3389/fsurg.2018.00080

Hinton, S., Catalano, P. J., Einhorn, L. H., Nichols, C. R., David Crawford, E., Vogelzang, N., . . . Loehrer, P. J., Sr. (2003). Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer, 97(8), 1869-1875. https://doi.org/10.1002/cncr.11271

Hinze, A. M., & Wigley, F. M. (2018). Pharmacotherapy Options in the Management of Raynaud's Phenomenon. Curr Treatm Opt Rheumatol, 4(3), 235-254. https://doi.org/10.1007/s40674-018-0102-6

Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018). Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. Sci Rep, 8(1), 2784. https://doi.org/10.1038/s41598-018-20993-y

Hofmockel, G., Gruss, A., & Theiss, M. (1996). Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urologia Internationalis, 57(1), 38-42. https://doi.org/10.1159/000282874

Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., . . . Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol, 29(8), 1658-1686. https://doi.org/10.1093/annonc/mdy217

Horwich, A., Fossa, S. D., Stenning, S., Bliss, J., & Hall, E. J. (2010). Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. J Clin Oncol, 28(7s), suppl; abstr 4538.

Horwich, A., Oliver, R. T., Wilkinson, P. M., Mead, G. M., Harland, S. J., Cullen, M. H., . . . Stenning, S. P. (2000). A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer, 83(12), 1623-1629. https://doi.org/10.1054/bjoc.2000.1498

S0007092000914988 [pii]

Houck, W., Abonour, R., Vance, G., & Einhorn, L. H. (2004). Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol, 22(11), 2155-2158. https://doi.org/10.1200/JCO.2004.11.054

Hu, B., & Daneshmand, S. (2018). Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. Adv Urol, 2018, 7978958. https://doi.org/10.1155/2018/7978958

Hu, B., Shah, S., Shojaei, S., & Daneshmand, S. (2015). Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. Clin Genitourin Cancer, 13(4), e265-e269. https://doi.org/10.1016/j.clgc.2015.01.002

Hu, R., Ulbright, T. M., & Young, R. H. (2019). Spermatocytic Seminoma: A Report of 85 Cases Emphasizing Its Morphologic Spectrum Including Some Aspects Not Widely Known. Am J Surg Pathol, 43(1), 1-11. https://doi.org/10.1097/PAS.0000000000001001

Huddart, R. A., Gabe, R., Cafferty, F. H., Pollock, P., White, J. D., Shamash, J., . . . National Cancer Research Institute Testis Cancer Clinical Studies, G. (2015). A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol, 67(3), 534-543. https://doi.org/10.1016/j.eururo.2014.06.034

Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 21(8), 1513-1523. https://doi.org/10.1200/JCO.2003.04.173

JCO.2003.04.173 [pii]

Huddart, R. A., O'Doherty, M. J., Padhani, A., Rustin, G. J., Mead, G. M., Joffe, J. K., . . . Group, N. T. T. C. S. (2007). 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol, 25(21), 3090-3095. https://doi.org/10.1200/JCO.2006.09.3831

ICRU, I. C. o. R. U. a. M. (1993). Prescribing, recording and reporting photon beam therapy report 50. Oxford University Press, Oxford, United Kingdom.

ICRU, I. C. o. R. U. a. M. (2010). Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83.  J ICRU.

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. (1997). J Clin Oncol, 15(2), 594-603.

Iwamoto, H., Izumi, K., Natsagdorj, A., Makino, T., Nohara, T., Shigehara, K., . . . Mizokami, A. (2018). Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. In Vivo, 32(4), 899-903. https://doi.org/10.21873/invivo.11326

Jacobsen, K. D., Ous, S., Waehre, H., Trasti, H., Stenwig, A. E., Lien, H. H., . . . Fossa, S. D. (1999). Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer, 80(1-2), 249-255. https://doi.org/10.1038/sj.bjc.6690347

Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2016). Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet, 55(3), 297-311. https://doi.org/10.1007/s40262-015-0319-6

Joel, S. P., Shah, R., Clark, P. I., & Slevin, M. L. (1996). Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol, 14(1), 257-267. https://doi.org/10.1200/JCO.1996.14.1.257

Jordan, B., Margulies, A., Cardoso, F., Cavaletti, G., Haugnes, H. S., Jahn, P., . . . office@eano.eu, E. G. C. E. a. (2020). Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol, 31(10), 1306-1319. https://doi.org/10.1016/j.annonc.2020.07.003

Kamischke, A., & Nieschlag, E. (2002). Update on medical treatment of ejaculatory disorders. Int J Androl, 25(6), 333-344. https://doi.org/10.1046/j.1365-2605.2002.00379.x

Kesler, K. A., Rieger, K. M., Hammoud, Z. T., Kruter, L. E., Perkins, S. M., Turrentine, M. W., . . . Brown, J. W. (2008). A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg, 85(2), 371-378. https://doi.org/10.1016/j.athoracsur.2007.09.020

Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., . . . Falanga, A. (2020). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 38(5), 496-520. https://doi.org/10.1200/JCO.19.01461

Khetpal, R., Katz, M. D., Cox, M., & Arnaoutakis, K. (2014). The role of salvage hemiscrotectomy in testicular cancer after scrotal contamination: a case report and literature review. Clin Genitourin Cancer, 12(3), e103-105. https://doi.org/10.1016/j.clgc.2013.12.004

Kier, M. G., Hansen, M. K., Lauritsen, J., Mortensen, M. S., Bandak, M., Agerbaek, M., . . . Daugaard, G. (2016). Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. JAMA Oncol, 2(12), 1624-1627. https://doi.org/10.1001/jamaoncol.2016.3651

Kleinschmidt, K., Dieckmann, K. P., Georgiew, A., Loy, V., & Weissbach, L. (2009). Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology, 77(1), 33-39. https://doi.org/10.1159/000218202

Klepp, O., Olsson, A. M., Ous, S., Nilsson, S., Hoisaether, P. A., & Tveter, K. (1991). Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol Nephrol, 25(3), 179-190.

Kliesch, S., Thomaidis, T., Schutte, B., Puhse, G., Kater, B., Roth, S., & Bergmann, M. (2003). Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS, 111(1), 70-74; discussion 75.

Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J. T., . . . Bokemeyer, C. (2004). Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol, 22(1), 108-114. https://doi.org/10.1200/JCO.2004.06.068

22/1/108 [pii]

Kollmannsberger, C., Daneshmand, S., So, A., Chi, K. N., Murray, N., Moore, C., . . . Nichols, C. (2010). Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol, 28(4), 537-542. 


Kollmannsberger, C., Moore, C., Chi, K. N., Murray, N., Daneshmand, S., Gleave, M., . . . Nichols, C. R. (2010). Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol, 21(6), 1296-1301. https://doi.org/10.1093/annonc/mdp473

Kollmannsberger, C., Nichols, C., Meisner, C., Mayer, F., Kanz, L., & Bokemeyer, C. (2000). Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 11(9), 1115-1120. https://doi.org/10.1023/a:1008333229936

Kollmannsberger, C., Tandstad, T., Bedard, P. L., Cohn-Cedermark, G., Chung, P. W., Jewett, M. A., . . . Nichols, C. R. (2015). Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol, 33(1), 51-57. https://doi.org/10.1200/JCO.2014.56.2116

Kollmannsberger, C., Tyldesley, S., Moore, C., Chi, K. N., Murray, N., Daneshmand, S., . . . Nichols, C. (2010). Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol


Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., . . . Motzer, R. J. (2005). Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 23(27), 6549-6555. 


Kvammen, O., Myklebust, T. A., Solberg, A., Moller, B., Klepp, O. H., Fossa, S. D., & Tandstad, T. (2016). Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor. Cancer Epidemiol Biomarkers Prev, 25(5), 773-779. https://doi.org/10.1158/1055-9965.EPI-15-1153

Kvammen, O., Myklebust, T. A., Solberg, A., Moller, B., Klepp, O. H., Fossa, S. D., & Tandstad, T. (2019). Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study. PLoS One, 14(12), e0225942. https://doi.org/10.1371/journal.pone.0225942

Langberg, M. K., Berglund-Nord, C., Cohn-Cedermark, G., Haugnes, H. S., Tandstad, T., & Langberg, C. W. (2018). Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA. Acta Oncol, 57(10), 1401-1406. https://doi.org/10.1080/0284186X.2018.1479072

Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008). Low serum testosterone and mortality in older men. J Clin Endocrinol Metab, 93(1), 68-75. https://doi.org/10.1210/jc.2007-1792

Leibovitch, I., Baniel, J., Foster, R. S., & Donohue, J. P. (1995). The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol, 154(3), 935-939.

Leu, L., & Baribeault, D. (2010). A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract, 16(3), 167-171. https://doi.org/10.1177/1078155209346071

Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., . . . Beyer, J. (2011). Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol, 29(16), 2178-2184. https://doi.org/10.1200/JCO.2010.32.6678

Lorch, A., Beyer, J., Bascoul-Mollevi, C., Kramar, A., Einhorn, L. H., Necchi, A., . . . Kollmannsberger, C. K. (2010). Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 28(33), 4906-4911. 


Lorch, A., Mollevi, A., Kramar, A., Einhorn, L. H., & Necchi, C. (2010). Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol, 28(15s), (suppl: abstr 4513).

Lotz, J. P., Bui, B., Gomez, F., Theodore, C., Caty, A., Fizazi, K., . . . Groupe d'Etudes des Tumeurs, U.-G. (2005). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol, 16(3), 411-418. https://doi.org/10.1093/annonc/mdi087

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63.

Luz, M. A., Kotb, A. F., Aldousari, S., Brimo, F., Tanguay, S., Kassouf, W., & Aprikian, A. G. (2010). Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol, 8, 97. https://doi.org/10.1186/1477-7819-8-97

Lyman, G. H., Bohlke, K., Falanga, A., & American Society of Clinical, O. (2015). Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract, 11(3), e442-444. https://doi.org/10.1200/JOP.2015.004473

Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Valkonen, V. P., . . . Salonen, J. T. (2004). Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27(5), 1036-1041. https://doi.org/10.2337/diacare.27.5.1036

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., . . . Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243. https://doi.org/10.1148/radiol.2017161659

Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., & Ansell, S. M. (2005). Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 23(30), 7614-7620. https://doi.org/10.1200/JCO.2005.02.7243

Masterson, T. A., & Cary, C. (2018). The Use of Modified Templates in Early and Advanced Stage Nonseminomatous Germ Cell Tumor. Adv Urol, 2018, 6783147. https://doi.org/10.1155/2018/6783147

Masterson, T. A., Shayegan, B., Carver, B. S., Bajorin, D. F., Feldman, D. R., Motzer, R. J., . . . Sheinfeld, J. (2012). Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology, 79(1), 156-159. https://doi.org/10.1016/j.urology.2011.09.038

McCaffrey, J. A., Mazumdar, M., Bajorin, D. F., Bosl, G. J., Vlamis, V., & Motzer, R. J. (1997). Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol, 15(7), 2559-2563.

McKenney, J. K., Heerema-McKenney, A., & Rouse, R. V. (2007). Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Advances in anatomic pathology, 14(2), 69-92. https://doi.org/10.1097/PAP.0b013e31803240e6

Measurements, I. I. C. o. R. U. a. (1999). Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). ICRU Report 62. Oxford University Press, Oxford, United Kingdom

Mezvrishvili, Z., & Managadze, L. (2006). Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol, 38(3-4), 615-619. https://doi.org/10.1007/s11255-005-4793-x

Miller, J. C., & Einhorn, L. H. (1990). Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol, 17(1 Suppl 2), 36-39.

Mineur, P., De Cooman, S., Hustin, J., Verhoeven, G., & De Hertogh, R. (1987). Feminizing testicular Leydig cell tumor: hormonal profile before and after unilateral orchidectomy. J Clin Endocrinol Metab, 64(4), 686-691. https://doi.org/10.1210/jcem-64-4-686

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 70(1), 93-105. https://doi.org/10.1016/j.eururo.2016.02.029

Moller, H., & Skakkebaek, N. E. (1999). Risk of testicular cancer in subfertile men: case-control study. BMJ, 318(7183), 559-562.

Mooney, K. L., & Kao, C. S. (2018). A Contemporary Review of Common Adult Non-germ Cell Tumors of the Testis and Paratestis. Surg Pathol Clin, 11(4), 739-758. https://doi.org/10.1016/j.path.2018.07.002

Mosharafa, A. A., Foster, R. S., Leibovich, B. C., Bihrle, R., Johnson, C., & Donohue, J. P. (2003). Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol, 169(6), 2126-2128. https://doi.org/10.1097/01.ju.0000060121.33899.4b

Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., . . . Bosl, G. J. (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 25(3), 247-256. https://pubmed.ncbi.nlm.nih.gov/17235042/


Murphy, B. R., Breeden, E. S., Donohue, J. P., Messemer, J., Walsh, W., Roth, B. J., & Einhorn, L. H. (1993). Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol, 11(2), 324-329. https://doi.org/10.1200/JCO.1993.11.2.324

Necchi, A., Lo Vullo, S., Giannatempo, P., Raggi, D., Calareso, G., Togliardi, E., . . . Salvioni, R. (2017). Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol, 28(6), 1346-1351. https://doi.org/10.1093/annonc/mdx124

Nichols, C. R. (1999). Treatment of recurrent germ cell tumors. Semin Surg Oncol, 17(4), 268-274. https://pubmed.ncbi.nlm.nih.gov/10588856/

Nichols, C. R., Roth, B., Albers, P., Einhorn, L. H., Foster, R., Daneshmand, S., . . . Kollmannsberger, C. (2013). Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol, 31(28), 3490-3493. https://doi.org/10.1200/JCO.2012.47.6010

Nicolai, N., Necchi, A., Gianni, L., Piva, L., Biasoni, D., Torelli, T., . . . Salvioni, R. (2009). Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int, 104(3), 340-346.


Nini, A., Konieczny, M., Winter, C., Lusch, A., Krauspe, R., & Albers, P. (2018). Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. Urol Oncol, 36(2), 82 e81-82 e85. https://doi.org/10.1016/j.urolonc.2017.10.016

Nonomura, N., Nagahara, A., Oka, D., Mukai, M., Nakai, Y., Nakayama, M., . . . Miki, T. (2009). Brain metastases from testicular germ cell tumors: a retrospective analysis. International journal of urology : official journal of the Japanese Urological Association, 16(11), 887-893. https://doi.org/10.1111/j.1442-2042.2009.02391.x

Nord, C., Bjoro, T., Ellingsen, D., Mykletun, A., Dahl, O., Klepp, O., . . . Fossa, S. D. (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol, 44(3), 322-328. https://doi.org/10.1016/s0302-2838(03)00263-x

Norway, C. R. o. (2019). Cancer in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway.

Nuver, J., Smit, A. J., Sleijfer, D. T., van Gessel, A. I., van Roon, A. M., van der Meer, J., . . . Gietema, J. A. (2004). Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer, 40(5), 701-706. https://doi.org/10.1016/j.ejca.2003.12.012

Nuver, J., Smit, A. J., Wolffenbuttel, B. H., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., & Gietema, J. A. (2005). The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol, 23(16), 3718-3725. 


O'Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., & Horwich, A. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol, 14(1), 91-96.

Oechsle, K., & Bokemeyer, C. (2011). Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am, 25(3), 605-613, ix. https://doi.org/10.1016/j.hoc.2011.03.012

Oechsle, K., Hartmann, M., Mehnert, A., Oing, C., Bokemeyer, C., & Vehling, S. (2016). Symptom burden in long-term germ cell tumor survivors. Support Care Cancer, 24(5), 2243-2250. https://doi.org/10.1007/s00520-015-3026-9

Oing, C., Giannatempo, P., Honecker, F., Oechsle, K., Bokemeyer, C., & Beyer, J. (2018). Palliative treatment of germ cell cancer. Cancer Treat Rev, 71, 102-107. https://doi.org/10.1016/j.ctrv.2018.10.007

Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Flechon, A., . . . Bokemeyer, C. (2014). Bone metastases in germ cell tumors: Results from an international data base. J Clin Oncol, (32), Supple; abstr 4559.

Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Flechon, A., . . . Bokemeyer, C. (2017). Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. Ann Oncol, 28(3), 576-582. https://doi.org/10.1093/annonc/mdw648

Oldenburg, J., Lorch, A., & Fossa, S. D. (2011). Late relapse of germ cell tumors. Hematol Oncol Clin North Am, 25(3), 615-626, x. 


Oldenburg, J., Wahlqvist, R., & Fossa, S. D. (2009). Late relapse of germ cell tumors. World Journal of Urology, 27(4), 493-500. https://doi.org/10.1007/s00345-009-0411-3

Oliver, R. T., Mason, M. D., Mead, G. M., von der Maase, H., Rustin, G. J., Joffe, J. K., . . . Stenning, S. P. (2005). Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 366(9482), 293-300. 


Oliver, R. T., Mead, G. M., Rustin, G. J., Joffe, J. K., Aass, N., Coleman, R., . . . Stenning, S. P. (2011). Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). J Clin Oncol, 29(8), 957-962.


Olofsson, S. E., Tandstad, T., Jerkeman, M., Dahl, O., Stahl, O., Klepp, O., . . . Cavallin-Stahl, E. (2011). Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol, 29(15), 2032-2039. https://doi.org/10.1200/JCO.2010.29.1278

Paffenholz, P., Grein, K., Heidegger, I., Nestler, T., Grabbert, M., Salem, J., . . . Heidenreich, A. (2019). Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World Journal of Urology, 37(9), 1907-1916. https://doi.org/10.1007/s00345-018-2598-7

Paffenholz, P., Pfister, D., & Heidenreich, A. (2020). Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia in situ. Transl Androl Urol, 9(Suppl 1), S24-S30. https://doi.org/10.21037/tau.2019.07.22

Patel, H. D., Singla, N., Ghandour, R. A., Freifeld, Y., Cheaib, J. G., Woldu, S. L., . . . Bagrodia, A. (2019). Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. Cancer, 125(22), 3947-3952. https://doi.org/10.1002/cncr.32427

Pearce, S. M., Golan, S., Gorin, M. A., Luckenbaugh, A. N., Williams, S. B., Ward, J. F., . . . Eggener, S. E. (2017). Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol, 71(3), 476-482. https://doi.org/10.1016/j.eururo.2016.05.017

Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., . . . Raptis, S. A. (2004). Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol, 46(2), 216-221. https://doi.org/10.1016/j.eururo.2004.03.001

S030228380400106X [pii]

Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., . . . Skarlos, D. (2004). Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol, 15(3), 493-497.

Pettus, J. A., Carver, B. S., Masterson, T., Stasi, J., & Sheinfeld, J. (2009). Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology, 73(2), 328-331; discussion 331-322. https://doi.org/10.1016/j.urology.2008.08.501

Pico, J. L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., . . . Biron, P. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol, 16(7), 1152-1159. 


Pierorazio, P. M., & Biles, M. J. (2019). Indications for Surgery in Disseminated Seminoma. Urol Clin North Am, 46(3), 399-407. https://doi.org/10.1016/j.ucl.2019.04.005

Pont, J., Albrecht, W., Postner, G., Sellner, F., Angel, K., & Holtl, W. (1996). Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 14(2), 441-448.

Puc, H. S., Heelan, R., Mazumdar, M., Herr, H., Scheinfeld, J., Vlamis, V., . . . Motzer, R. J. (1996). Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol, 14(2), 454-460.

Quek, M. L., Simma-Chiang, V., Stein, J. P., Pinski, J., Quinn, D. I., & Skinner, D. G. (2005). Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther, 5(5), 869-874. https://doi.org/10.1586/14737140.5.5.869

Raggi, D., Giannatempo, P., Miceli, R., Fare, E., Piva, L., Biasoni, D., . . . Necchi, A. (2017). Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. Am J Clin Oncol, 40(1), 60-65. https://doi.org/10.1097/COC.0000000000000113

Ravi, R., Ong, J., Oliver, R. T., Badenoch, D. F., Fowler, C. G., & Hendry, W. F. (1999). The management of residual masses after chemotherapy in metastatic seminoma. BJU Int, 83(6), 649-653.

Risk, M. C., & Foster, R. S. (2011). Postchemotherapy retroperitoneal lymph node dissection for testis cancer. Expert Rev Anticancer Ther, 11(1), 95-106. https://doi.org/10.1586/era.10.206

Roth, L. M., & Cheng, L. (2018). Classical gonadoblastoma: its relationship to the 'dissecting' variant and undifferentiated gonadal tissue. Histopathology, 72(4), 545-555. https://doi.org/10.1111/his.13387

Ruf, C. G., Sanatgar, N., Isbarn, H., Ruf, B., Simon, J., Fankhauser, C. D., & Dieckmann, K. P. (2020). Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World Journal of Urology. https://doi.org/10.1007/s00345-020-03079-1

Rutgers, J. L., Young, R. H., & Scully, R. E. (1988). The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol, 12(7), 503-513.

Sakaguchi, Y., & Isowa, N. (2012). Successful resection of mediastinal seminoma evaluated the response to induction chemotherapy with fluorodeoxyglucose-positron emission tomography. Ann Thorac Cardiovasc Surg, 18(1), 45-47. https://doi.org/10.5761/atcs.cr.11.01667

Sawrie, S. M., Guthrie, B. L., Spencer, S. A., Nordal, R. A., Meredith, R. F., Markert, J. M., . . . Fiveash, J. B. (2008). Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys, 70(1), 181-186. https://doi.org/10.1016/j.ijrobp.2007.05.084

Saxman, S. B., Nichols, C. R., & Einhorn, L. H. (1997). Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest, 111(3), 657-660. https://doi.org/10.1378/chest.111.3.657

Schirren, J., Trainer, S., Eberlein, M., Lorch, A., Beyer, J., & Bolukbas, S. (2012). The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg, 60(6), 405-412. https://doi.org/10.1055/s-0031-1299584

Schmoll, H. J. (2002). Extragonadal germ cell tumors. Ann Oncol, 13 Suppl 4, 265-272. https://doi.org/10.1093/annonc/mdf669

Schmoll, H. J., Kollmannsberger, C., Metzner, B., Hartmann, J. T., Schleucher, N., Schoffski, P., . . . German Testicular Cancer Study, G. (2003). Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol, 21(22), 4083-4091. https://doi.org/10.1200/JCO.2003.09.035

Schneider, D. T., Schuster, A. E., Fritsch, M. K., Hu, J., Olson, T., Lauer, S., . . . Perlman, E. J. (2001). Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer Res, 61(19), 7268-7276.

Scholz, M., Zehender, M., Thalmann, G. N., Borner, M., Thoni, H., & Studer, U. E. (2002). Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol, 13(1), 121-124. https://doi.org/10.1093/annonc/mdf003

Schultz, S. M., Einhorn, L. H., Conces, D. J., Jr., Williams, S. D., & Loehrer, P. J. (1989). Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol, 7(10), 1497-1503.

Sharmeen, F., Rosenthal, M. H., & Howard, S. A. (2014). The management of retroperitoneal lymphadenopathy in spermatocytic seminoma of the testicle. Clin Imaging, 38(2), 202-204. https://doi.org/10.1016/j.clinimag.2013.11.006

Sharp, D. S., Carver, B. S., Eggener, S. E., Kondagunta, G. V., Motzer, R. J., Bosl, G. J., & Sheinfeld, J. (2008). Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol, 26(34), 5524-5529.


Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006). Low serum testosterone and mortality in male veterans. Arch Intern Med, 166(15), 1660-1665. https://doi.org/10.1001/archinte.166.15.1660

Simone, C. B., 2nd, Kramer, K., O'Meara, W. P., Bekelman, J. E., Belard, A., McDonough, J., & O'Connell, J. (2012). Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys, 82(1), 242-249. https://doi.org/10.1016/j.ijrobp.2010.11.021

Skoogh, J., Steineck, G., Cavallin-Stahl, E., Wilderang, U., Hakansson, U. K., Johansson, B., . . . Swenoteca. (2011). Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. International Journal of Andrology, 34(2), 183-192. 

Sleijfer, S. (2001). Bleomycin-induced pneumonitis. Chest, 120(2), 617-624.

Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., . . . Alliance for Clinical Trials in, O. (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 309(13), 1359-1367. https://doi.org/10.1001/jama.2013.2813

Socialstyrelsen. (2019). Cancer Incidence in Sweden 2018.

Sohaib, S. A., Koh, D. M., Barbachano, Y., Parikh, J., Husband, J. E., Dearnaley, D. P., . . . Huddart, R. (2009). Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol, 64(4), 362-367. https://doi.org/10.1016/j.crad.2008.10.011

Spermon, J. R., De Geus-Oei, L. F., Kiemeney, L. A., Witjes, J. A., & Oyen, W. J. (2002). The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 89(6), 549-556.

Spiess, P. E., Brown, G. A., Liu, P., Tannir, N. M., Tu, S. M., Evans, J. G., . . . Pisters, L. L. (2006). Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer, 107(7), 1483-1490. https://doi.org/10.1002/cncr.22182

Sprauten, M., Haugnes, H. S., Brydoy, M., Kiserud, C., Tandstad, T., Bjoro, T., . . . Oldenburg, J. (2015). Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol, 26(10), 2133-2140. https://doi.org/10.1093/annonc/mdv328

Srikanthan, A., Tran, B., Beausoleil, M., Jewett, M. A., Hamilton, R. J., Sturgeon, J. F., . . . Bedard, P. L. (2015). Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol, 33(6), 582-587. https://doi.org/10.1200/JCO.2014.58.6537

Stang, A., Trabert, B., Wentzensen, N., Cook, M. B., Rusner, C., Oosterhuis, J. W., & McGlynn, K. A. (2012). Gonadal and extragonadal germ cell tumours in the United States, 1973-2007. Int J Androl, 35(4), 616-625. https://doi.org/10.1111/j.1365-2605.2011.01245.x

Steiner, H., Holtl, L., Wirtenberger, W., Berger, A. P., Bartsch, G., & Hobisch, A. (2002). Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology, 60(2), 324-328.

Steiner, H., Scheiber, K., Berger, A. P., Rein, P., Hobisch, A., Aufderklamm, J., . . . Zangerl, F. (2011). Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int, 107(7), 1074-1079. https://doi.org/10.1111/j.1464-410X.2010.09658.x

Stepanian, S., Patel, M., & Porter, J. (2016). Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique. Eur Urol, 70(4), 661-667. https://doi.org/10.1016/j.eururo.2016.03.031

Stephenson, A. J., Bosl, G. J., Motzer, R. J., Bajorin, D. F., Stasi, J. P., & Sheinfeld, J. (2007). Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol, 25(35), 5597-5602. https://doi.org/10.1200/JCO.2007.12.0808

Sturgeon, J. F., Moore, M. J., Kakiashvili, D. M., Duran, I., Anson-Cartwright, L. C., Berthold, D. R., . . . Jewett, M. A. (2010). Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience. Eur Urol


Svartberg, J., von Muhlen, D., Schirmer, H., Barrett-Connor, E., Sundfjord, J., & Jorde, R. (2004). Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol, 150(1), 65-71. https://doi.org/10.1530/eje.0.1500065

Tandstad, T., Cavallin-Stahl, E., Dahl, O., Haugnes, H. S., Langberg, C., Laurell, A., . . . Cohn-Cedermark, G. (2014). Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA. J Clin Oncol, 32(5s), suppl; abstract 4508.

Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., . . . Klepp, O. (2009). Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol, 27(13), 2122-2128. 


Tandstad, T., Smaaland, R., Solberg, A., Bremnes, R. M., Langberg, C. W., Laurell, A., . . . Cohn-Cedermark, G. (2011). Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol, 29(6), 719-725. 


Tandstad, T., Stahl, O., Dahl, O., Haugnes, H. S., Hakansson, U., Karlsdottir, A., . . . Swenoteca. (2016). Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy, a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. https://doi.org/10.1093/annonc/mdw164

Tandstad, T., Stahl, O., Hakansson, U., Dahl, O., Haugnes, H. S., Klepp, O. H., . . . Swenoteca. (2014). One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol, 25(11), 2167-2172. https://doi.org/10.1093/annonc/mdu375

Thompson, R. H., Carver, B. S., Bosl, G. J., Bajorin, D., Motzer, R., Feldman, D., . . . Sheinfeld, J. (2010). Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer, 116(22), 5243-5250. https://doi.org/10.1002/cncr.25266

Thorsen, L., Haugnes HS, Fosså SD, Brydoy M, Tandstad T, Wisløff T, Gjerset GM, Edvardsen E, Larsen K, Sandset PM, Henriksson CA, Raastad T, Negaard H. (2020). Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature. Int J Cancer, In press.

Tookman, L., Rashid, S., Matakidou, A., Phillips, M., Wilson, P., Ansell, W., . . . Shamash, J. (2013). Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta Oncol, 52(5), 987-993. https://doi.org/10.3109/0284186X.2012.714078

Trama, A., Mallone, S., Nicolai, N., Necchi, A., Schaapveld, M., Gietema, J., . . . Group, R. W. (2012). Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. Eur J Cancer, 48(2), 159-169. https://doi.org/10.1016/j.ejca.2011.08.020

Tryakin, A., Fedyanin, M., Kanagavel, D., Fainstein, I., Sergeev, J., Polockij, B., . . . Tjulandin, S. (2011). Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Urology, 78(3), 620-625. https://doi.org/10.1016/j.urology.2011.05.005

Ueno, T., Tanaka, Y. O., Nagata, M., Tsunoda, H., Anno, I., Ishikawa, S., . . . Itai, Y. (2004). Spectrum of germ cell tumors: from head to toe. Radiographics, 24(2), 387-404. https://doi.org/10.1148/rg.242035082

Utz, D. C., & Buscemi, M. F. (1971). Extragonadal testicular tumors. J Urol, 105(2), 271-274. https://doi.org/10.1016/s0022-5347(17)61508-8

van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T., . . . van Leeuwen, F. E. (2006). Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 24(3), 467-475. 


van Dijk, M. R., Steyerberg, E. W., & Habbema, J. D. (2006). Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer, 42(7), 820-826. 


Vaughn, D. J., Hwang, W. T., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015). Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer, 121(9), 1463-1468. https://doi.org/10.1002/cncr.29213

Vuky, J., Bains, M., Bacik, J., Higgins, G., Bajorin, D. F., Mazumdar, M., . . . Motzer, R. J. (2001). Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol, 19(3), 682-688. https://doi.org/10.1200/JCO.2001.19.3.682

Warde, P., Specht, L., Horwich, A., Oliver, T., Panzarella, T., Gospodarowicz, M., & von der Maase, H. (2002). Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol, 20(22), 4448-4452.

Weibring, K., Nord, C., Stahl, O., Eberhard, J., Sandberg, K., Johansson, H., . . . Cohn-Cedermark, G. (2019). Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann Oncol, 30(4), 604-611. https://doi.org/10.1093/annonc/mdz017

Weijl, N. I., Rutten, M. F., Zwinderman, A. H., Keizer, H. J., Nooy, M. A., Rosendaal, F. R., . . . Osanto, S. (2000). Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol, 18(10), 2169-2178. https://doi.org/10.1200/JCO.2000.18.10.2169

Weissbach, L., Bussar-Maatz, R., & Mann, K. (1997). The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol, 32(1), 16-22.

Wethal, T., Kjekshus, J., Roislien, J., Ueland, T., Andreassen, A. K., Wergeland, R., . . . Fossa, S. D. (2007). Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv, 1(1), 8-16. https://doi.org/10.1007/s11764-007-0012-3

Widen, S. E., & Erlandsson, S. I. (2004). Self-reported tinnitus and noise sensitivity among adolescents in Sweden. Noise Health, 7(25), 29-40.

Wierecky, J., Kollmannsberger, C., Boehlke, I., Kuczyk, M., Schleicher, J., Schleucher, N., . . . Bokemeyer, C. (2005). Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol, 131(4), 255-260. https://doi.org/10.1007/s00432-004-0628-x

Wilder, R. B., Buyyounouski, M. K., Efstathiou, J. A., & Beard, C. J. (2012). Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys, 83(4), e445-452. https://doi.org/10.1016/j.ijrobp.2012.01.044

Zagars, G. K., Ballo, M. T., Lee, A. K., & Strom, S. S. (2004). Mortality after cure of testicular seminoma. J Clin Oncol, 22(4), 640-647. https://doi.org/10.1200/JCO.2004.05.205

JCO.2004.05.205 [pii]

Zhang, M., Kao, C. S., Ulbright, T. M., & Epstein, J. I. (2013). Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. Am J Surg Pathol, 37(8), 1208-1214. https://doi.org/10.1097/PAS.0b013e318286c129

Zhou, E. S., Hall, K. T., Michaud, A. L., Blackmon, J. E., Partridge, A. H., & Recklitis, C. J. (2019). Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer, 27(6), 2179-2187. https://doi.org/10.1007/s00520-018-4477-6

Zilli, T., Boudreau, C., Doucet, R., Alizadeh, M., Lambert, C., van Nguyen, T., & Taussky, D. (2011). Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncol, 50(4), 555-562. https://doi.org/10.3109/0284186x.2011.564650

Siste faglige endring: 15. april 2021